1. ESOPEC Trial (Oesophagal Cancer) Neoadjuvant chemoradiotherapy may have underperformed due to radiotherapy quality issues (e.
1. ESOPEC Trial (Oesophagal Cancer)
Neoadjuvant chemoradiotherapy may have underperformed due to radiotherapy quality issues (e.g., lymphopenia). Do not abandon the CROSS approach yet—patient selection remains key.
2. ORCHESTRA Trial (Metastatic CRC)
Adding tumour debulking to chemotherapy in multiorgan metastatic CRC does not improve outcomes → systemic therapy remains the mainstay.
3. Rare Pancreatic Cancer – Targeted Therapy
Molecular profiling of rare subtypes is opening new precision treatment pathways, highlighting heterogeneity in pancreatic cancer.
4. Federated Learning in Rare Tumours
Global collaboration without sharing patient data is now possible → enables large-scale research in rare cancers with privacy preserved.
5. PERISCOPE II Trial (Gastric Cancer)
CRS + HIPEC does not improve survival in gastric cancer with peritoneal spread and increases toxicity → systemic therapy remains standard.
6. AI-Based Treatment Selection (PDAC)
AI models can personalise second-line therapy →
FOLFIRINOX for fit patients
Nal-IRI + 5FU for selected subgroups
7. BBOpCo Trial (MSS Colorectal Cancer)
First signal that immunotherapy may work in MSS CRC → opens door for biomarkers and combination strategies.
8. Organoids in Oncology
Patient-derived organoids may reduce drug failure rates and improve personalised therapy → future of translational oncology.
9. FLOT + Durvalumab (Gastroesophageal Cancer)
Now approved → new perioperative standard, aiming to improve cure rates.
10. Aspirin in PIK3CA-Mutated CRC
Adjuvant aspirin shows DFS benefit in selected patients → strong move toward biomarker-driven therapy.
Introduction: Circulating tumor DNA (ctDNA) has emerged as a promising noninvasive biomarker for monitoring treatment response and residual disease in solid tumors. However, its prognostic value during neoadjuvant chemotherapy (NAC) for localized pancreatic ductal adenocarcinoma...
Introduction: Aspirin is one of the few interventions proven to reduce colorectal and other Lynch syndrome–associated cancers. The earlier CaPP2 trial established 600 mg daily aspirin as an effective chemopreventive strategy, but concerns regarding long-term...
Introduction: The TOPAZ-1 trial established durvalumab combined with gemcitabine and cisplatin (GemCis) as the first immunotherapy-based first-line standard of care for advanced biliary tract cancer (BTC). However, long-term survival outcomes and durability of benefit beyond...
Introduction: Somatostatin receptor (SSTR) PET/CT has become indispensable for diagnosing, staging, and monitoring neuroendocrine tumors (NETs). However, until now, there has been no standardized method for assessing treatment response using SSTR PET imaging. This international...
Introduction: Staging laparoscopy (SL) is recommended for patients with locally advanced gastric cancer to detect occult peritoneal metastases before curative treatment. However, its real-world utilization across Europe remains uncertain. This large GASTRODATA study evaluated the...
Introduction: Neoadjuvant immune checkpoint inhibitors have transformed the management of mismatch repair-deficient (dMMR) or microsatellite instability-high (MSI-H) locally advanced colorectal cancer, achieving unprecedented pathological response rates. Experimental evidence suggests that cyclooxygenase-2 (COX-2) inhibition may enhance...
We are pioneers in clinical intelligence, dedicated to helping gastroenterologists harness the power of artificial intelligence to drive precision, efficiency, and patient growth.